Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 9/20 | 0.51 |
| ▸ | WDR77 | Q9BQA1 | 9/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25581154 | 1.00 | PRMT5 (0.51) | PRMT5WDR77PARP1KDM4ELMNA | |
| SCHEMBL24661307 | 0.83 | SMN1; SMN2 (0.41) | PRMT5WDR77LMNAAAK1 | |
| SCHEMBL25218307 | 0.83 | BRD4 (0.37) | PRMT5WDR77PARP1KDM4ELMNA | |
| SCHEMBL23087948 | 0.82 | PRMT5 (0.66) | PRMT5WDR77PARP1KDM4ELMNA | |
| SCHEMBL27386026 | 0.80 | PRMT5 (0.50) | PRMT5WDR77PARP1KDM4ELMNA | |
| SCHEMBL30752865 | 0.80 | PRMT5 (0.50) | PRMT5WDR77PARP1KDM4ELMNA | |
| SCHEMBL27385996 | 0.79 | PRMT5 (0.48) | PRMT5WDR77PARP1KDM4ELMNA | |
| SCHEMBL16814130 | 0.75 | AAK1 (0.51) | PRMT5WDR77KDM4ELMNAAAK1 | |
| SCHEMBL29918736 | 0.75 | AAK1 (0.51) | PRMT5WDR77KDM4ELMNAAAK1 | |
| SCHEMBL2943289 | 0.74 | AAK1 (0.45) | PRMT5WDR77KDM4ELMNAAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408088-A1 | PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2024-12-12 | — | — | US | disclosed |
| EP-4442680-A1 | PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | Abbisko Therapeutics Co., Ltd. (CN) | 2024-10-09 | — | — | EP | disclosed |
| WO-2023098439-A1 | PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 上海和誉生物医药科技有限公司 | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408088-A1 | PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | PRMT5, PRMT1, PRMT8 | PRMT5 1/4885WDR77 38/4885PARP1 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.